ArticleCell death & disease2026
OTUD6B-mediated K48 deubiquitination of FXR1 forms a positive feedback loop activating MEK2/ERK signaling in colorectal cancer liver metastasis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Liver metastasis remains a major cause of mortality in patients with colorectal cancer (CRC). Here, we identify OTUD6B, a deubiquitinating enzyme of the OTU family, as a key driver of CRC liver metastasis. OTUD6B is upregulated in metastatic CRC tissues and is correlated with poor prognosis. Functionally, OTUD6B promotes CRC cell proliferation, migration, and invasion in vitro and enhances tumor growth and liver metastasis in vivo. Mechanistically, OTUD6B binds the KH domain of fragile X-related protein 1 (FXR1) via its N-terminal region and stabilizes FXR1 by removing K48-linked polyubiquitin chains in a catalytic activity-dependent manner. In turn, FXR1 binds and stabilizes MEK2 mRNA, leading to increased MEK2 expression and activation of ERK signaling. Notably, FXR1 also upregulates OTUD6B expression, establishing a feed-forward loop that amplifies the oncogenic OTUD6B-FXR1-MEK2/ERK axis. OTUD6B, FXR1, and MEK2 levels are positively correlated in clinical CRC liver metastasis samples. Crucially, the MEK2 inhibitor U0126 acts synergistically with OTUD6B silencing to suppress liver metastasis. Collectively, these findings delineate a previously unrecognized oncogenic cascade in which OTUD6B stabilizes FXR1 to activate MEK2/ERK signaling, thereby driving CRC liver metastasis. Dual targeting of OTUD6B and MEK2 may represent a promising therapeutic strategy for advanced CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.